Xeris Biopharma Holdings, Inc.
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodicā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.13
Price+0.62%
$0.05
1Y
Price
Market Cap
$1.404b
Small
Price/Earnings 3y Avg5y Avg
128x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+14.8%
EBITDA Margin+2.7%
Net Profit Margin+11.5%
Free Cash Flow Margin+14.8%
EBITDA Margin+2.7%
Net Profit Margin+11.5%
Free Cash Flow MarginRevenue
$314.853m
+7.9%
1y CAGR+25.2%
3y CAGR+31.0%
5y CAGREarnings
$12.008m
+2067.5%
1y CAGR+726.8%
3y CAGR+553.7%
5y CAGREPS
$0.07
-
1y CAGR+39.3%
3y CAGR+38.4%
5y CAGRBook Value
$13.011m
$392.013m
Assets$379.002m
Liabilities$37.329m
DebtDebt to Assets
9.5%
0.8x
Debt to EBITDAFree Cash Flow
$47.227m
+69.1%
1y CAGR+88.7%
3y CAGR+79.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company